Table 1.
Included papers.
| No | Author | Sample Size | Sample Type | ASRM Stage * | Control Group Characteristics | Methods | Normalization Control | |
|---|---|---|---|---|---|---|---|---|
| 1 | Wang et al., 2013 [20] |
Cases Controls |
60 25 |
Serum | I–IV | NLP ILP: severe DM, PM, IF |
1. Microarray 2. RT-qPCR |
U6 snRNA |
| 2 | Hsu et al., 2014 [21] |
Cases Controls |
40 25 |
Serum | II–IV | NLP ILP: OBGP |
1. Microarray 2. RT-qPCR |
18s RNA |
| 3 | Cho et al., 2015 [22] |
Cases Controls |
24 24 |
Serum | III–IV | NLP ILP: PM, PP, SE, IF, OBGP |
RT-qPCR | U6 snRNA |
| 4 | Cosar et al., 2016 [23] |
Cases Controls |
24 24 |
Serum | III–IV | NLP ILP: PM, PP, IF, SE |
1. Microarray 2. RT-qPCR |
U6 snRNA |
| 5 | Wang et al., 2016 [24] |
Cases Controls |
30 20 |
Serum | I–II | NLP ILP: PM, IF |
1. Solexa sequencing 2. RT-qPCR |
Cel-miR-39 |
| 6 | Nothnick et al., 2017 [25] |
Cases Controls |
41 40 |
Serum | I–IV | n = 20: NLP ILP: PP, pain with bleeding n = 20: (SR)HW |
RT-qPCR | U6 snRNA |
| 7 | Maged et al., 2018 [26] |
Cases Controls |
45 35 |
Serum | I–IV | NLP ILP: PP, IF, benign neoplasms |
RT-qPCR | U6 snRNA |
| 8 | Hu et al., 2019 [27] |
Cases Controls |
20 26 |
Serum | III–IV | NLP or NLT ILP or ILT: PM, PP, IF, SE |
RT-qPCR | U6 snRNA |
| 9 | Moustafa et al., 2020 [28] |
Cases Controls |
41 59 |
Serum | I–IV | NLP ILP: OBGP |
RT-qPCR | U6 snRNA |
| 10 | Pang et al., 2020 [29] |
Cases Controls |
20 30 |
Serum | NS | Uterine fibroids, endometriosis free (NFS) | NS | NS |
| 11 | Misir et al., 2021 [30] |
Cases Controls |
71 65 |
Serum | I–IV | NLP or NLT | RT-qPCR | U6 snRNA |
| 12 | He et al., 2022 [31] |
Cases Controls |
23 20 |
Serum | I–IV | Tubal obstruction with NLP | RT-qPCR | U6 snRNA |
| 13 | Neuhausser et al., 2022 [32] | 1. DC Cases Controls 2. VC Cases Controls |
21 24 27 24 |
Serum | NS | Asymptomatic egg donors with normal pelvic US | 1. NanoString nCounter 2. RT-qPCR |
U6 snRNA |
| 14 | Kumari et al., 2022 [33] |
Cases Controls |
10 10 |
Serum | NS | NLP or NLT ILP: PP, SE, PM, IF, OBGP |
RT-qPCR | miR-39 |
| 15 | Lin et al., 2023 [34] |
Cases Controls |
80 80 |
Serum | I-IV | HW: normal gynecological examination and US | RT-qPCR | U6 snRNA |
| 16 | Yang et al., 2023 [35] | Cases Controls |
17 13 |
Serum | NS | HT for uterine fibroids or CIN grade II-III | RT-qPCR | U6 snRNA |
| 17 | Suryawanshi et al., 2013 [36] |
Cases Controls |
33 20 |
Plasma | NS | SRHW | 1. RT-qPCR 2. RT-qPCR |
miR-132 |
| 18 | Jia et al., 2013 [37] |
Cases Controls |
23 23 |
Plasma | III–IV | NLP ILP: PM, PP, IF, UL |
1. Microarray 2. RT-qPCR |
miR-16 |
| 19 | Rekker et al., 2015 [38] |
Cases Controls |
61 65 |
Plasma | I–IV | n = 35: NLP ILP: SE, DM, IF, PP, polycystic ovaries n = 30: SRHW |
RT-qPCR | miR-30e-5p, miR-99a-5p |
| 20 | Bashti et al., 2018 [39] |
Cases Controls |
55 23 |
Plasma | I–IV | NLP ILP: prolapsed uterus, ovarian cyst, urinary incontinence |
RT-qPCR | miR-103-3p |
| 21 | Wang et al., 2018 [40] |
Cases Controls |
80 60 |
Plasma | I–IV | NLP ILP: SE, PM, PP, IF, UL |
RT-qPCR | Beta-actin |
| 22 | Pateisky et al., 2018 [41] | Cases Controls |
51 41 |
Plasma | I–IV | NLP ILP: SE, PP, IF, adnexal cysts, uterine fibroids |
q-PCR-array based microarrays | miR-199a |
| 23 | Nisenblat et al., 2019 [42] | 1.Cases Controls 2.a) Cases Controls 2.b) Cases Controls 3.Cases Controls 4.Cases Controls |
8 8 8 8 10 10 51 27 80 39 |
Plasma | I–IV | 1. Asymptomatic (SR)HW 2.a) Asymptomatic (SR)HW 2.b) NLP ILP: PP and/or IF 3. NLP ILP: DM, DP, chronic PP, IF 4. NLP ILP: DM, DP, chronic PP |
1. Microarray 2. RT-qPCR |
miR-30b |
| 24 | Vanhie et al., 2019 [43] |
1. DC Cases Controls 2. VC Cases Controls |
82 38 60 30 |
Plasma | I–IV | NLP ILP: surgical treatment of endometriosis diagnosed on imaging or diagnostic laparoscopy, PP with SE, IF |
1. NGS 2. RT-qPCR 3. RT-qPCR |
hsa-miR-423-3p, hsa-miR-28-3p |
| 25 | Hossein Razi et al., 2019 [44] |
Cases Controls |
25 25 |
Plasma | III–IV | NLP ILP: PP, ovarian cyst |
1. NGS 2. RT-qPCR |
SNORD47 |
| 26 | Papari et al., 2020 [45] |
Cases Controls |
25 28 |
Plasma | III–IV | NLP ILP: PM, PM, IF, UL |
RT-qPCR | hsa-miR-148b-3p, hsa-miR-30e-5p |
| 27 | Gu et al., 2020 [46] |
Cases Controls |
19 21 |
Plasma | Ovarian endometriosis, NS | HW (NFS) | RT-qPCR | NS |
| 28 | Zafari et al., 2021 [47] |
Cases Controls |
25 25 |
Plasma | III-IV | NLP ILP: PP, IF, DM |
RT-qPCR | miR-16 |
| 29 | Bahramy et al., 2021 [48] |
Cases Controls |
30 30 |
Plasma | III–IV | NLP ILP: PP, IF, DM |
RT-qPCR | miR-16 |
| 30 | Bendifallah et al., 2022 [49] | Cases Controls |
153 47 |
Plasma | I–IV | Negative MRI and NLP ILP: OBGP, SE |
NGS | NS |
| 31 | Tahermanesh et al., 2023 [50] | Cases Controls |
30 30 |
Plasma | III-IV | HW with NLP | RT-qPCR | U6 snRNA |
| 32 | Walasik et al., 2023 [51] | Cases Controls |
24 25 |
Plasma | III-IV | PM, OBGP, HW, NLP | RT-qPCR | miR-39 |
* Endometriosis stage in cases, according to the revised American Society for Reproductive Medicine (ASRM) classification [19]. Abbreviations: NLP = negative laparoscopy for endometriosis; NLT = negative laparotomy for endometriosis; ILP = indication for laparoscopy; ILT = indication for laparotomy; PP = pelvic pain; PM = pelvic mass; OBGP = other benign gynecological pathology; SE = suspected for endometriosis; IF = infertility; DM = dysmenorrhea; DP = dyspareunia; UL = uterine leiomyoma; EEC = endometrioid endometrial cancer; EOC = endometrioid ovarian carcinoma; US = ultrasonography; HW = healthy women; SRHW = self-reported healthy women; HT = hysterectomy; CIN = cervical intraepithelial neoplasia; OS = ovarian stimulation; NS = not specified; NFS = not further specified; NGS = next-generation sequencing; RT-qPCR = reverse transcription–quantitative polymerase chain reaction; U6 snRNA = U6 small nuclear RNA; DC = discovery cohort; VC = validation cohort.